Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 42Urinary Bladder Neoplasms 18Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 11Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Breast Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Fallopian Tube Neoplasms 9Lung Neoplasms 8Carcinoma, Transitional Cell 8Biliary Tract Neoplasms 7Recurrence 6Gallbladder Neoplasms 6Neoplasms 5Cholangiocarcinoma 5Non-Muscle Invasive Bladder Neoplasms 4Colorectal Neoplasms 4Urothelial Cancer 3Stomach Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Adenocarcinoma 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

camrelizumab 1apatinib 1Tegafur 1Surgical Procedures, Operative 1Oxaliplatin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Biliary Tract Carcinoma × Gemcitabine × Clear all
NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Advanced Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡